antiandrogens/fatigue

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

Bls 1 frá 54 niðurstöður

Antiandrogen monotherapy: indications and results.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Many patients with prostate cancer for whom hormonal therapy is indicated are still physically and sexually active; quality of life is therefore a vital issue when considering treatment options. Traditional castration-based therapies, although effective, have implications with respect to quality of

Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Sexuality, aggression, and mood were investigated in 14 presurgical male-to-female transsexuals, undergoing antiandrogenic treatment with anandron, a pure antiandrogen. Subjects were given a test battery the morning prior to treatment onset and after 8 weeks of treatment. In addition they were

Influence of a six month endurance exercise program on the immune function of prostate cancer patients undergoing Antiandrogen- or Chemotherapy: design and rationale of the ProImmun study.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Exercise seems to minimize prostate cancer specific mortality risk and treatment related side effects like fatigue and incontinence. However the influence of physical activity on the immunological level remains uncertain. Even prostate cancer patients undergoing palliative treatment often

Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Although antiandrogen withdrawal has moderate efficacy in patients with hormone refractory prostate carcinoma (HRPC), the effect of the simultaneous suppression of adrenal androgens with ketoconazole at the time of antiandrogen withdrawal is not known. METHODS Twenty consecutive patients

Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy?

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Androgen suppressive maneuvers still represent the gold standard for prostate cancer patients. However, they are associated with side effects (fatigue, sexual impotence, hot flushes, anemia, anxiety, depression and osteoporosis) all of which have a negative impact on quality of life. Nonsteroidal

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Non-steroidal antiandrogens and castration are the main therapy options for advanced stages of prostate cancer. However, debate regarding the value of these treatment options continues. OBJECTIVE To assess the effects of non-steroidal antiandrogen monotherapy compared with luteinising

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear translocation and AR binding to androgen response elements and, unlike bicalutamide, does not exhibit agonist properties in the context of AR

Enzalutamide: a novel antiandrogen for patients with castrate-resistant prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Enzalutamide (MDV3100, Xtandi, Medivation\Astellas) is an oral inhibitor of androgen receptor signaling that blocks androgen receptor interaction, inhibits translocation of the androgen receptor to the nucleus, impairs androgen receptor binding to DNA, and inhibits coactivator recruitment and

Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background: Enzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is

A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Phosphatase and tensin homologue (PTEN) loss is common in advanced prostate cancer, leading to constitutive activation of the PI3 kinase pathway. Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a key signaling node in this pathway; its

Bicalutamide-induced hepatotoxicity: A rare adverse effect.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

METHODS Male, 81 FINAL DIAGNOSIS: Prostate cancer Symptoms: Anorexia • dark urine • joundice • letargy METHODS Casodex Clinical Procedure: - Specialty: Oncology. OBJECTIVE Adverse events of drug therapy. BACKGROUND Bicalutamide is a nonsteroidal anti-androgen used extensively during the initiation

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Salivary duct carcinoma (SDC) is a rare, aggressive head and neck cancer with frequent metastases. Current treatment options for recurrent or metastatic SDC include targeted anti-androgen therapy, HER2-targeted therapy, or systemic chemotherapy. We report the first use of a combination

Use of cyproterone acetate in prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Cyproterone acetate is a progestational antiandrogen with potent antigonadotropic activity that results in rapid suppression of serum testosterone. Used as a single agent, cyproterone acetate yields a total androgen blockade. It may be combined with low-dose diethylstilbestrol, orchiectomy, or LHRH

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE To exploit the favorable dose intensity and safety profile of weekly paclitaxel, we conducted a Phase I trial of paclitaxel by 3-hour infusion in combination with estramustine phosphate (EM) in men with hormone-refractory prostate cancer (HRPC). The antimicrotubule drug combination of

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND BMS-275291 is a selective matrix metalloproteinase inhibitor (MMPI) that does not inhibit sheddases implicated in the dose-limiting arthritis of older MMPIs. We conducted a randomized phase II trial of two doses of BMS-275291 (1,200 versus 2,400 mg) in hormone-refractory prostate cancer

Fyrri
1
2
3
4
Næst

Skráðu þig á
facebook síðu okkar

Herbal & Natural Medicine

Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum

Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum

Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum